INVESTOR ALERT: Investigation of ACADIA Pharmaceuticals Inc. Announced by Glancy Binkow & Goldberg LLP

Glancy Binkow & Goldberg LLP announces that it is investigating potential claims on behalf of investors of ACADIA Pharmaceuticals, Inc. (“ACADIA” or the “Company”) (NASDAQ:ACAD) concerning possible violations of federal securities laws. The investigation is focused on certain statements issued by the Company concerning ACADIA’s operations and financial prospects.

Please contact Lesley Portnoy at (888) 773-9224 or (310) 201-9150, or at shareholders@glancylaw.com to discuss this matter. If you inquire by email please include your mailing address, telephone number and number of shares purchased.

ACADIA is a biopharmaceutical company focused on the development and commercialization of small molecule drugs that address unmet medical needs in neurological and related central nervous system disorders. The Company’s lead product candidate is NUPLAZID for the treatment of Parkinson’s disease psychosis.

On March 11, 2015, the Company announced that ACADIA plans to submit its New Drug Application (NDA) for NUPLAZID for the treatment of Parkinson’s disease psychosis in the second half of 2015 − rather than the first quarter of 2015 as previously planned. According to the Company, the decision to move back the planned submission is based on “additional time required to complete the preparation of systems to support commercial manufacturing and supply and, in turn, to support the U.S. Food and Drug Administration’s (FDA) review of NUPLAZID.” In a separate press release the Company announced that Uli Hacksell has retired as ACADIA’s chief executive officer and as a member of the board of directors. Following this news, ACADIA shares declined more than 22%, or $9.94 per share, to close at $34.82 per share on March 12, 2015.

If you purchased ACADIA securities, if you have information or would like to learn more about these claims, or have any questions concerning this announcement or your rights or interests with respect to these matters, please contact Lesley Portnoy, Esquire, of Glancy Binkow & Goldberg LLP, 1925 Century Park East, Suite 2100, Los Angeles, California 90067 at (310) 201-9150, Toll Free at (888) 773-9224, by e-mail to shareholders@glancylaw.com, or visit our website at http://www.glancylaw.com. If you inquire by email please include your mailing address, telephone number and number of shares purchased.

This press release may be considered Attorney Advertising in some jurisdictions under the applicable law and ethical rules.